Advertisement

Pharmacokinetics of progesterone in postmenopausal women

2. Pharmacokinetics following percutaneous administration
  • C. Mircioiu
  • A. Perju
  • E. Griu
  • G. Calin
  • A. Neagu
  • D. Enachescu
  • D. S. Miron
Article

Summary

Progesterone was administered percutaneously to postmenopausal women in topical applications on the breast and chest areas in a hydrophilic (gel), lipophilic and an emulsion type base. Venous blood samples were taken 2, 4, 6, 24, 48 and 72 h following administration. The plasma levels were evaluated by radioimmunoassay. Time of maximum concentration (tmax) was, in all cases, in the neighborhood of 4 h. Mean peak plasma concentrations were: 1 ng/ml for the lipophilic, 1.24 ng/ml for the hydrophilic and 2.26 ng/ml for the emulsion type base. The areas under the curves (AUCs) were practically equivalent for the first two methods, but higher values were obtained for administration in the emulsion type base. The elimination was slow, with a half-time varying in the range of 30–40 h for all three types of base, a value that was much higher than those obtained after administration of progesterone via vaginal suppositories. The AUCs were parallel with the peak plasma concentrations: almost 2-fold higher for emulsion than for the gel and lipophilic base. Fit for plasma levels using mono-, bi- and tricompartmental models furnished acceptable results only in the case of monocompartmental model, which raises a number of physiological and physico-chemical considerations. A ‘pseudomonocompartmental’ model was constructed to explain this ‘anomaly’.

Keywords

Progesterone pharmacokinetics percutaneous administration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mauvais-Jarvis P., Vickers C.F.H., Wepierre J. (Eds) (1980): Percutaneous absorption of steroids. London: Academic Press.Google Scholar
  2. 2.
    Kincl F.A., Ciaccio L.A., Benagiano G. (1978): Increasing oral bioavailability of progesterone by formulation. J. Steroid Biochem., 9, 83–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Nillius S.J., Johansson E.D.B. (1971): Plasma levels of progesterone after vaginal, rectal or intramuscular administration of progesterone. Am. J. Obstet. Gynecol., 110, 470–477.PubMedGoogle Scholar
  4. 4.
    Maddocks S., Hahn P., Moller F., Reid R.L. (1986): A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am. J. Obstet. Gynecol., 154, 573–576.PubMedGoogle Scholar
  5. 5.
    Mircioiu C., Perju A., Griu E., Calin G., Neagu A., Enachescu D. (1998): Pharmacokinetics of progesterone in postmenopausal women. 1. Pharmacokinetics following intravaginal administration. Eur. J. Drug Metab. Pharmacokinet., 23, 391–396.PubMedGoogle Scholar
  6. 6.
    Heinzel G., Woloszczak R., Thomann P. (1993): Pharmacokinetic and pharmacodynamic data analysis system. Stuttgart: Gustav Fischer.Google Scholar
  7. 7.
    Mircioiu C., Perju A., Enachescu D., Griu E., Neagu A. (1993): Biodisposition and pharmacokinetics of percutaneous and intravaginal progesterone. Correlation with in vitro measurements. Third International Conference on Prediction penetration, La Grande Motte, France, 14–16 April 1993.Google Scholar
  8. 8.
    Morville R., Dray F., Regnier J., Barrat J. (1982): Biodisponibilité de la Progesterone naturelle administré par voie orale. Mesuré de la conc. du steroid dans le plasma, l’endometre et la tissue mammaire. J. Gynecol. Obstet. Biol. Reprod., 11, 55–63.Google Scholar
  9. 9.
    Thijssen J.H., Zander J. (1966): Progesteron 4C and its metabolites in the blood after intravenous injections into woman. Acta Endocrinol., 51, 563–567.PubMedGoogle Scholar
  10. 10.
    Siddiqui O., Roberts M., Polack A.E. (1989): Percutaneous absorption of steroids: relative contributions of epidermal penetration and dermal clearance. J. Pharmacokinet. Biopharmacol., 17, 405–424.CrossRefGoogle Scholar
  11. 11.
    Archer D.F., Fahy G.E., Viniegra-Sibal A. (1995): Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am. J. Obstet. Gynecol., 173, 471–478.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • C. Mircioiu
    • 1
  • A. Perju
    • 1
  • E. Griu
    • 1
  • G. Calin
    • 1
  • A. Neagu
    • 1
  • D. Enachescu
    • 2
  • D. S. Miron
    • 1
  1. 1.Faculty of PharmacyCarol Davila University of Medicine and PharmacyBucharestRomania
  2. 2.Faculty of MathematicsUniversity of BucharestBucharestRomania

Personalised recommendations